Literature DB >> 3508560

Investigation of the gastrointestinal transit and in vivo drug release of isosorbide-5-nitrate pellets.

W Fischer1, A Boertz, S S Davis, R Khosla, W Cawello, K Sandrock, G Cordes.   

Abstract

An oral formulation of controlled-release isosorbide-5-nitrate pellets has been used to investigate the location of pellets in the gastrointestinal (GI) tract and, in parallel, to measure the drug absorption from these locations. Using the method of gamma scintigraphy the transit times and spreading of pellets in the GI tract have been determined. The method of numeric deconvolution was applied to calculate the drug input into the systemic circulation. The results indicate that a well-absorbed substance such as isosorbide-5-nitrate is absorbed from the stomach and small intestinal in a manner that is controlled by the properties of the pellets. Drug absorption is reduced in the colon. The average transit time from mouth to colon is 6 to 8 hr, which represents the maximum acceptable time for drug release for this oral controlled-release preparation. Taking into account these relations an isosorbide-5-nitrate pellet formulation with a bioavailability of 84% has been developed that maintained the minimal therapeutic plasma level for more than 16 hr after application.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3508560     DOI: 10.1023/a:1016423404636

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  3 in total

1.  Transit of pharmaceutical dosage forms through the small intestine.

Authors:  S S Davis; J G Hardy; J W Fara
Journal:  Gut       Date:  1986-08       Impact factor: 23.059

2.  The use of gamma scintigraphy to follow the gastrointestinal transit of pharmaceutical formulations.

Authors:  F N Christensen; S S Davis; J G Hardy; M J Taylor; D R Whalley; C G Wilson
Journal:  J Pharm Pharmacol       Date:  1985-02       Impact factor: 3.765

3.  Metabolic fact of 14C-isosorbide 5-mononitrate in humans.

Authors:  S G Wood; B A John; L F Chasseaud; R M Major; M E Forrest; R Bonn; A Darragh; R F Lambe
Journal:  Arzneimittelforschung       Date:  1984
  3 in total
  4 in total

Review 1.  Gamma scintigraphy in the evaluation of pharmaceutical dosage forms.

Authors:  S S Davis; J G Hardy; S P Newman; I R Wilding
Journal:  Eur J Nucl Med       Date:  1992

Review 2.  Development of long-acting nitrate delivery systems.

Authors:  U E Jonsson
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Plasma concentrations of remoxipride and the gastrointestinal transit of 111In-marked extended-release coated spheres.

Authors:  C Graffner; Z Wagner; M I Nilsson; E Widerlöv
Journal:  Pharm Res       Date:  1990-01       Impact factor: 4.200

4.  Release and absorption characteristics of novel theophylline sustained-release formulations: in vitro-in vivo correlation.

Authors:  Z Hussein; M Friedman
Journal:  Pharm Res       Date:  1990-11       Impact factor: 4.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.